Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.54 |
| ▸ | ASAH1 | Q13510 | 10/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5495838 | 1.00 | IDO1 (0.54) | IDO1ASAH1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL17201488 | 0.85 | IDO1 (0.54) | IDO1ASAH1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL6810615 | 0.83 | IDO1 (0.49) | IDO1ASAH1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL6810618 | 0.83 | IDO1 (0.49) | IDO1ASAH1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL5503209 | 0.81 | IDO1 (0.50) | IDO1ASAH1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL5503210 | 0.81 | IDO1 (0.50) | IDO1ASAH1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL5500885 | 0.81 | IDO1 (0.50) | IDO1ASAH1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL5504041 | 0.81 | IDO1 (0.50) | IDO1ASAH1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL5500883 | 0.81 | IDO1 (0.50) | IDO1ASAH1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL5499815 | 0.80 | IDO1 (0.49) | IDO1ASAH1ALDH1A1MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1754700-A2 | Synthesis of oligoketides | Kosan Biosciences, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-7022825-B2 | Polyketides and antibiotics | KOSAN BIOSCIENCES, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20030096374-A1 | Preparation of ketide ester; obtain benzoxazolone derivative, incubate with polyketide synthase, recover ketide oligomer | ASHLEY GARY (US) | 2003-05-22 | — | — | US | disclosed |
| US-20030092140-A1 | Novel polyketides and antibiotics | ASHLEY GARY (US) | 2003-05-15 | — | — | US | disclosed |
| US-6492562-B1 | INVENTION ALSO RELATES TO NOVEL INTERMEDIATES AND THE RESULTING MODIFIED POLYKETIDES AND ANTIBIOTICS. | KOSAN BIOSCIENCES, INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096374-A1 | Preparation of ketide ester; obtain benzoxazolone derivative, incubate with polyketide synthase, recover ketide oligomer | COASY, KARS1, ACOT7 | IDO1 3584/4885ASAH1 1660/4885ALDH1A1 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.